================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): March 1, 2006

                       ROCKWELL MEDICAL TECHNOLOGIES, INC.
            ---------------------------------------------------------
             (Exact name of registrant as specified in its charter)

           Michigan                 000-230-661                 38-3317208
 ----------------------------      -------------          --------------------
 (State or other jurisdiction       (Commission               (IRS Employer
      of incorporation)             File Number)           Identification No.)

            30142 Wixom Road, Michigan                            48334
------------------------------------------------               ------------
    (Address of principal executive offices)                    (Zip Code)

        Registrant's telephone number, including area code (248) 960-9009

                                 Not applicable
        -----------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 2.02      RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

     On March 1, 2006, the Company issued the press release attached hereto
Exhibit 99.1, announcing its financial results for the quarter ended December
31, 2005.

ITEM 7.01      REGULATION FD DISCLOSURE.

     On March 1, 2006, the Company issued the press release attached hereto
Exhibit 99.1, announcing its financial results for the quarter ended December
31, 2005.

ITEM 9.01      FINANCIAL STATEMENTS AND EXHIBITS

(d)  Exhibit Number

99.1           Press Release dated March 1, 2006

                                        2


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           ROCKWELL MEDICAL TECHNOLOGIES, INC.

Date:  March 1, 2006                       By: /S/ Thomas E. Klema
                                               ---------------------------------
                                               Thomas E. Klema
                                               Its: Chief Financial Officer

                                        3